US2013296366A1PendingUtilityA1
Optical isomers of an iloperidone metabolite
Est. expiryAug 31, 2021(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/18A61P 25/00C07D 413/04
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A pharmaceutical composition comprising (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl]-ethanol or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier or diluent.
2 . A method for treating a psychotic disorder in a human subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl]-ethanol or a pharmaceutically acceptable salt thereof.
3 . The method of claim 2 , wherein the psychotic disorder is schizophrenia or bipolar disorder.
4 . A process for the production of the compound of Formula II:
or a pharmaceutically acceptable salt thereof;
comprising reduction of iloperidone of formula III:
with an optically active boran complex of formula compound of Formula IV:
and recovering the resulting compound or a pharmaceutically acceptable salt thereof.
5 . The process of claim 4 , further comprising production of the compound of Formula IV:
by reacting a compound of Formula V:
with borane-dimethylsulfide complex.Join the waitlist — get patent alerts
Track US2013296366A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.